Incyte Corp (INCY) 107.98 $INCY
37.7% Return Seen to Date on SmarTrend Incyte Call (INCY)
Comtex SmarTrend(R) - 1 hr 39 mins ago
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on January 23rd, 2015 at $78.42. In approximately 3 months, Incyte has returned 37.69% as of today's recent price of $107.98.
INCY: 107.98 (-1.20)
Will Agenus (AGEN) Disappoint in Q1 Earning Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:30PM CDT
Agenus (AGEN) is expected to report first-quarter 2015 results on Apr 23.
AGEN: 6.08 (+0.21), BIIB: 423.57 (+1.46), INCY: 107.98 (-1.20), IMGN: 9.96 (+0.01)
Insider Trading Alert - STFC, KFS And INCY Traded By Insiders
at The Street - Wed Apr 22, 9:30AM CDT
Stocks with insider trader activity include STFC, KFS and INCY
STFC: 23.83 (-0.01), INCY: 107.98 (-1.20), KFS: 5.56 (-0.03)
Watch for Incyte to Potentially Pullback After Gaining 3.48% Yesterday
Comtex SmarTrend(R) - Tue Apr 21, 5:35PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $104.73 to a high of $109.89. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $105.96 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 107.98 (-1.20)
Incyte's Emerging Development Pipeline Described in Eleven Abstracts at 2015 AACR Annual Meeting
Business Wire - Fri Apr 17, 6:30AM CDT
--Incyte's FGFR, BRD and PIM inhibitor programs described
INCY: 107.98 (-1.20)
Look for Shares of Incyte to Potentially Pullback after Yesterday's 2.46% Rise
Comtex SmarTrend(R) - Thu Apr 16, 4:08PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $100.40 to a high of $103.74. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $102.79 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 107.98 (-1.20)
Incyte Has Returned 27.9% Since SmarTrend Recommendation (INCY)
Comtex SmarTrend(R) - Wed Apr 15, 11:07AM CDT
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on January 23rd, 2015 at $78.42. In approximately 3 months, Incyte has returned 27.91% as of today's recent price of $100.31.
INCY: 107.98 (-1.20)
Incyte Joins SAFE-BioPharma Association
Business Wire - Wed Apr 15, 6:38AM CDT
SAFE-BioPharma Association (www.safe-biopharma.org), the non-profit industry coalition responsible for the on-going development and implementation of the SAFE-BioPharma(R) digital identity and signature standard, today announced that Incyte Corporation has joined SAFE-BioPharma.
INCY: 107.98 (-1.20)
Incyte to Report First Quarter Financial Results on April 30
Business Wire - Tue Apr 14, 7:00AM CDT
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter 2015 financial results conference call for 8:00 a.m. ET on Thursday, April 30, 2015. The schedule for the press release and conference call is as follows:
INCY: 107.98 (-1.20)
Incyte to Establish European Headquarters in Geneva, Switzerland
Business Wire - Tue Apr 14, 6:30AM CDT
--Location provides efficient access to key clinical trial experts and institutions
INCY: 107.98 (-1.20)
Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015
M2 - Tue Apr 14, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrmrmr/tyrosine_kinase) has announced the addition of the "Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015" report to their offering. Tyrosine kinase therapeutics segment is rapidly growing along with numerous products at various phases of industry life cycle. Huge investments in research and development segment could be attributed as main reason behind growth of this market segment. As a result, several products are at different stages of clinical trials which will be introduced in market in coming years. Some tyrosine kinase medical care products including mAbs are costly to produce but large patient base and superior pharmacological benefits are some factors responsible for continuous growth of this market segment. Development and discovery of innovative technologies for commercialization is increasing because of large financial inputs. As a result, more therapeutic options will be available to patients at cost effective rates. Their disease coverage is increasing continuously due to which their market penetration is expected to increase several folds in coming years. Increasing disease incidences especially cancer has attracted several pharmaceutical companies to invest in this segment. Imatinib (protein-tyrosine kinase inhibitor) for CML treatment by Novartis was the first of this kind to enter in global market. Targeted therapeutics offer superior pharmacological benefits due to which profit margin of tyrosine kinase inhibitors are expected to increase in coming years. Small molecule based targeted therapeutics will offer competition to monoclonal antibodies in terms of pharmacological efficacy but pricing and commercialization strategies are also expected to play a major role. Monoclonal antibodies are widely accepted across the globe due to higher safety and efficacy profiles along with minimized side effects. Several mAbs biding to different tyrosine receptors have been formulated by pharmaceutical companies generating significant revenues across the globe. For instance, Genentech's trastuzumab binds to HER2 for breast cancer treatment while Bevacizumab binds to VEGF to treat NSCLC. Pharmaceutical companies are developing cancer drugs to target same receptor kinase due to which severe competition would be found in certain categories. EFGR is widely studied due to which majority of tyrosine kinase therapeutics belong to this category. Moreover, it is involved in breast cancer which has well developed market so revenues generated by this segment are expected to be significantly higher than other cancer categories. Clinical pipeline of tyrosine kinase therapeutics is quite strong due to which competitive product are expected to enter continuously in global market. Owing to increasing disease incidences, it has become imperative to take necessary steps to introduce innovative tyrosine kinase therapeutics in global market. Technological advancements may allow the investigators to develop products having high safety and efficacy levels along with minimized side effects but it will take some time. Various products are at different stages of clinical trials which will be introduced in global market in coming years. Higher cost effectiveness is expected due to which sales is expected to increase and profit margins will increase. With all these development, the future of tyrosine kinase therapeutics looks optimistic. Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015 Report Highlights: - Global Tyrosine Kinase Therapeutics Market Overview - Mechanism of Tyrosine Kinase Therapeutics - Global Tyrosine Kinase Inhibitors Pipeline by Company, Indication & Phase - Global Tyrosine Kinase Inhibitors Pipeline: 557 Drugs - Majority Drugs in Preclinical Phase: 239 Drugs - Marketed Tyrosine Kinase Inhibitors: 58 Drugs - Marketed Tyrosine Kinase Inhibitors Clinical Analysis by Company & Indication Companies Mentioned - Advenchen Laboratories - Array Pharmaceuticals - AstraZeneca - Bayer Healthcare Pharmaceuticals - Biogen Idec - Bristol-Myer Squibb - Boehringer Ingelheim - Chugai Pharmaceutical - Celgene Corporation - Exelixis - Incyte Corporation - GalaxoSmithKline - Johnson & Johnson - Merck - Novartis - Onyx pharmaceuticals - Pfizer - Sanofi - Tolero Pharmaceutical - QIAGEN For more information visit http://www.researchandmarkets.com/research/hr...ine_kinase
JNJ: 100.43 (+0.13), BIIB: 423.57 (+1.46), MRK: 57.69 (+0.03), INCY: 107.98 (-1.20), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
Oncogene Inhibitors Therapy Market & Pipeline Insight 2015
M2 - Tue Apr 14, 6:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v4ktq5/oncogene) has announced the addition of the "Oncogene Inhibitors Therapy Market & Pipeline Insight 2015" report to their offering. Oncogenomics is an emerging field that involves screening of genes that may be involved in cancer development. Human genome consists of 23 chromosomal pairs, approximately 20,000- 25,000 genes and 3,234.83 Mb genome size. Oncogene addiction is a phenomenon in which cancer could be checked by deactivating single oncogene. Proto-onco genes are main target of investigators because they may convert into oncogenes at any stage of life. Sequence level similarity and identification of genetic factors are expected to shed more light on their working. It will allow the investigators to develop drugs capable of preventing oncogene activation and activity in the body. Development of such therapeutics is a daunting task because human genome is quite big and consists of variety of genes whose function has yet to be determined by investigators. Oncogene Inhibitor market is a rapidly growing segment with numerous products at different stages of clinical pipeline and marketed products at different phases of industry life cycle. Pharmaceutical companies are trying to provide efficient medical care to patients and generate significant revenues by their sales. Large patient base and superior technology are some important factors responsible for continuous growth of this market segment across the globe. Several competitors are available for wide range of malignancies which further makes it imperative for them to provide both therapeutic and financial benefit to the patients. Due to which large numbers of pharmaceutical companies are expected to improve their products to achieve higher sales. Significant investments in research and development segment could also be attributed as the main reason behind its growth. As a result, several innovative products are under investigation which would be introduced in market after passing pre described clinical end points and criteria's set by regulatory authorities. Researchers are trying to develop new formulations to have better safety and efficacy profiles along with minimized side effects. Number of oncogene inhibitor for treatment of different malignancies is increasing every year due to which their market shares are expected to increase several folds in coming years. Escalating competition could be considered as one of the biggest driver for oncogene inhibitor therapeutics because this segment has significantly large number of products. Different oncogene inhibitors have been successfully commercialized by different pharmaceutical companies in past few decades. Oncogenes like c-met and c-myc are one of the most commonly used targets for inhibitors due their involvement in various cancers. This biological phenomenon has given rise to therapeutics which could be commercialized for different cancer categories. In this way, more revenues could be generated and competition could be offered to other cancer therapeutics due to superior therapeutic efficacy. Ras gene was one of the earliest oncogene identified by investigators known to have proto-oncogenic in nature. However, therapeutic for this gene not available in market due to its complex protein structure that is impregnable by oncogenic inhibitors. Report Highlights: - Global Oncogene Inhibitors Market Overview - Oncogene Inhibitors Pipeline by Company, Indication & Phase - Oncogene Inhibitors Pipeline: 185 Drugs - Majority Oncogene Inhibitors in Preclinical Phase: 105 Drugs - Proto Oncogene Protein c met Inhibitors Pipeline: 42 Drugs - Proto Oncogene Protein c-akt Inhibitors: 39 Drugs - Marketed Oncogene Inhibitors: 22 Drugs - Marketed Proto-Oncogene Protein c-bcl-2 Inhibitors: 8 Drugs Companies Mentioned - ArQule Inc - AstraZeneca - Biogen Idec - Boehringer Ingelheim - Celgene Corporation - Constellation Pharmaceutical - Epizyme Pharmaceutical - GalaxoSmithKline - Genentech - Incyte Corporation - Johnson & Johnson - Merck - Novartis - Onyx pharmaceuticals - Pfizer For more information visit http://www.researchandmarkets.com/research/v4ktq5/oncogene
JNJ: 100.43 (+0.13), BIIB: 423.57 (+1.46), MRK: 57.69 (+0.03), INCY: 107.98 (-1.20), ARQL: 2.11 (-0.03), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
Incyte (INCY) Is Strong On High Volume Today
at The Street - Mon Apr 13, 9:06AM CDT
Trade-Ideas LLC identified Incyte (INCY) as a strong on high relative volume candidate
INCY: 107.98 (-1.20)
10 Largest Companies by Market Cap in Biotech
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 11, 2:02PM CDT
Source: Celgene Big bucks are being made in biotech. That's clear from the sizzling performance of the industry. If five years ago you had invested $1,000 each in the current 10 biggest biotechs in terms of market cap, you would now have over...
BIIB: 423.57 (+1.46), VRTX: 132.85 (+0.65), PCYC: 256.98 (-0.77), BMRN: 121.08 (-0.16), GILD: 104.18 (-1.02), INCY: 107.98 (-1.20), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ABBV: 64.52 (+0.91), REGN: 472.63 (+9.41), CELG: 115.54 (+0.72)
The Reason Behind Geron Corporation's 25% Catapult Higher in March
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 09, 7:03AM CDT
What: Shares of Geron , a clinical-stage biopharmaceutical company currently developing an experimental drug known as imetelstat to fight hematologic myeloid malignancies, rocketed 25% higher in March, based on data from S&P Capital IQ ,...
JNJ: 100.43 (+0.13), GERN: 4.20 (-0.04), INCY: 107.98 (-1.20)
Incyte Rises 2.16% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 08, 4:45PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $89.34 to a high of $92.14. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $91.32 on volume of 730,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 107.98 (-1.20)
Incyte Set to Possibly Pullback After Yesterday's Rally of 2.16%
Comtex SmarTrend(R) - Wed Apr 08, 4:44PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $89.34 to a high of $92.14. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $91.32 on volume of 730,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 107.98 (-1.20)
Shares of INCY Up 15.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 08, 10:05AM CDT
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on January 23rd, 2015 at $78.42. In approximately 3 months, Incyte has returned 15.61% as of today's recent price of $90.66.
INCY: 107.98 (-1.20)
37.7% Return Seen to Date on SmarTrend Incyte Call (INCY)
Comtex SmarTrend(R) - 1 hr 39 mins ago
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on January 23rd, 2015 at $78.42. In approximately 3 months, Incyte has returned 37.69% as of today's recent price of $107.98.
INCY: 107.98 (-1.20)
Will Agenus (AGEN) Disappoint in Q1 Earning Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:30PM CDT
Agenus (AGEN) is expected to report first-quarter 2015 results on Apr 23.
AGEN: 6.08 (+0.21), BIIB: 423.57 (+1.46), INCY: 107.98 (-1.20), IMGN: 9.96 (+0.01)
Insider Trading Alert - STFC, KFS And INCY Traded By Insiders
at The Street - Wed Apr 22, 9:30AM CDT
Stocks with insider trader activity include STFC, KFS and INCY
STFC: 23.83 (-0.01), INCY: 107.98 (-1.20), KFS: 5.56 (-0.03)
Watch for Incyte to Potentially Pullback After Gaining 3.48% Yesterday
Comtex SmarTrend(R) - Tue Apr 21, 5:35PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $104.73 to a high of $109.89. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $105.96 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 107.98 (-1.20)
Incyte's Emerging Development Pipeline Described in Eleven Abstracts at 2015 AACR Annual Meeting
Business Wire - Fri Apr 17, 6:30AM CDT
--Incyte's FGFR, BRD and PIM inhibitor programs described
INCY: 107.98 (-1.20)
Look for Shares of Incyte to Potentially Pullback after Yesterday's 2.46% Rise
Comtex SmarTrend(R) - Thu Apr 16, 4:08PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $100.40 to a high of $103.74. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $102.79 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 107.98 (-1.20)
Incyte Has Returned 27.9% Since SmarTrend Recommendation (INCY)
Comtex SmarTrend(R) - Wed Apr 15, 11:07AM CDT
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on January 23rd, 2015 at $78.42. In approximately 3 months, Incyte has returned 27.91% as of today's recent price of $100.31.
INCY: 107.98 (-1.20)
Incyte Joins SAFE-BioPharma Association
Business Wire - Wed Apr 15, 6:38AM CDT
SAFE-BioPharma Association (www.safe-biopharma.org), the non-profit industry coalition responsible for the on-going development and implementation of the SAFE-BioPharma(R) digital identity and signature standard, today announced that Incyte Corporation has joined SAFE-BioPharma.
INCY: 107.98 (-1.20)
Incyte to Report First Quarter Financial Results on April 30
Business Wire - Tue Apr 14, 7:00AM CDT
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter 2015 financial results conference call for 8:00 a.m. ET on Thursday, April 30, 2015. The schedule for the press release and conference call is as follows:
INCY: 107.98 (-1.20)
Incyte to Establish European Headquarters in Geneva, Switzerland
Business Wire - Tue Apr 14, 6:30AM CDT
--Location provides efficient access to key clinical trial experts and institutions
INCY: 107.98 (-1.20)
Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015
M2 - Tue Apr 14, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrmrmr/tyrosine_kinase) has announced the addition of the "Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015" report to their offering. Tyrosine kinase therapeutics segment is rapidly growing along with numerous products at various phases of industry life cycle. Huge investments in research and development segment could be attributed as main reason behind growth of this market segment. As a result, several products are at different stages of clinical trials which will be introduced in market in coming years. Some tyrosine kinase medical care products including mAbs are costly to produce but large patient base and superior pharmacological benefits are some factors responsible for continuous growth of this market segment. Development and discovery of innovative technologies for commercialization is increasing because of large financial inputs. As a result, more therapeutic options will be available to patients at cost effective rates. Their disease coverage is increasing continuously due to which their market penetration is expected to increase several folds in coming years. Increasing disease incidences especially cancer has attracted several pharmaceutical companies to invest in this segment. Imatinib (protein-tyrosine kinase inhibitor) for CML treatment by Novartis was the first of this kind to enter in global market. Targeted therapeutics offer superior pharmacological benefits due to which profit margin of tyrosine kinase inhibitors are expected to increase in coming years. Small molecule based targeted therapeutics will offer competition to monoclonal antibodies in terms of pharmacological efficacy but pricing and commercialization strategies are also expected to play a major role. Monoclonal antibodies are widely accepted across the globe due to higher safety and efficacy profiles along with minimized side effects. Several mAbs biding to different tyrosine receptors have been formulated by pharmaceutical companies generating significant revenues across the globe. For instance, Genentech's trastuzumab binds to HER2 for breast cancer treatment while Bevacizumab binds to VEGF to treat NSCLC. Pharmaceutical companies are developing cancer drugs to target same receptor kinase due to which severe competition would be found in certain categories. EFGR is widely studied due to which majority of tyrosine kinase therapeutics belong to this category. Moreover, it is involved in breast cancer which has well developed market so revenues generated by this segment are expected to be significantly higher than other cancer categories. Clinical pipeline of tyrosine kinase therapeutics is quite strong due to which competitive product are expected to enter continuously in global market. Owing to increasing disease incidences, it has become imperative to take necessary steps to introduce innovative tyrosine kinase therapeutics in global market. Technological advancements may allow the investigators to develop products having high safety and efficacy levels along with minimized side effects but it will take some time. Various products are at different stages of clinical trials which will be introduced in global market in coming years. Higher cost effectiveness is expected due to which sales is expected to increase and profit margins will increase. With all these development, the future of tyrosine kinase therapeutics looks optimistic. Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015 Report Highlights: - Global Tyrosine Kinase Therapeutics Market Overview - Mechanism of Tyrosine Kinase Therapeutics - Global Tyrosine Kinase Inhibitors Pipeline by Company, Indication & Phase - Global Tyrosine Kinase Inhibitors Pipeline: 557 Drugs - Majority Drugs in Preclinical Phase: 239 Drugs - Marketed Tyrosine Kinase Inhibitors: 58 Drugs - Marketed Tyrosine Kinase Inhibitors Clinical Analysis by Company & Indication Companies Mentioned - Advenchen Laboratories - Array Pharmaceuticals - AstraZeneca - Bayer Healthcare Pharmaceuticals - Biogen Idec - Bristol-Myer Squibb - Boehringer Ingelheim - Chugai Pharmaceutical - Celgene Corporation - Exelixis - Incyte Corporation - GalaxoSmithKline - Johnson & Johnson - Merck - Novartis - Onyx pharmaceuticals - Pfizer - Sanofi - Tolero Pharmaceutical - QIAGEN For more information visit http://www.researchandmarkets.com/research/hr...ine_kinase
JNJ: 100.43 (+0.13), BIIB: 423.57 (+1.46), MRK: 57.69 (+0.03), INCY: 107.98 (-1.20), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
Oncogene Inhibitors Therapy Market & Pipeline Insight 2015
M2 - Tue Apr 14, 6:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v4ktq5/oncogene) has announced the addition of the "Oncogene Inhibitors Therapy Market & Pipeline Insight 2015" report to their offering. Oncogenomics is an emerging field that involves screening of genes that may be involved in cancer development. Human genome consists of 23 chromosomal pairs, approximately 20,000- 25,000 genes and 3,234.83 Mb genome size. Oncogene addiction is a phenomenon in which cancer could be checked by deactivating single oncogene. Proto-onco genes are main target of investigators because they may convert into oncogenes at any stage of life. Sequence level similarity and identification of genetic factors are expected to shed more light on their working. It will allow the investigators to develop drugs capable of preventing oncogene activation and activity in the body. Development of such therapeutics is a daunting task because human genome is quite big and consists of variety of genes whose function has yet to be determined by investigators. Oncogene Inhibitor market is a rapidly growing segment with numerous products at different stages of clinical pipeline and marketed products at different phases of industry life cycle. Pharmaceutical companies are trying to provide efficient medical care to patients and generate significant revenues by their sales. Large patient base and superior technology are some important factors responsible for continuous growth of this market segment across the globe. Several competitors are available for wide range of malignancies which further makes it imperative for them to provide both therapeutic and financial benefit to the patients. Due to which large numbers of pharmaceutical companies are expected to improve their products to achieve higher sales. Significant investments in research and development segment could also be attributed as the main reason behind its growth. As a result, several innovative products are under investigation which would be introduced in market after passing pre described clinical end points and criteria's set by regulatory authorities. Researchers are trying to develop new formulations to have better safety and efficacy profiles along with minimized side effects. Number of oncogene inhibitor for treatment of different malignancies is increasing every year due to which their market shares are expected to increase several folds in coming years. Escalating competition could be considered as one of the biggest driver for oncogene inhibitor therapeutics because this segment has significantly large number of products. Different oncogene inhibitors have been successfully commercialized by different pharmaceutical companies in past few decades. Oncogenes like c-met and c-myc are one of the most commonly used targets for inhibitors due their involvement in various cancers. This biological phenomenon has given rise to therapeutics which could be commercialized for different cancer categories. In this way, more revenues could be generated and competition could be offered to other cancer therapeutics due to superior therapeutic efficacy. Ras gene was one of the earliest oncogene identified by investigators known to have proto-oncogenic in nature. However, therapeutic for this gene not available in market due to its complex protein structure that is impregnable by oncogenic inhibitors. Report Highlights: - Global Oncogene Inhibitors Market Overview - Oncogene Inhibitors Pipeline by Company, Indication & Phase - Oncogene Inhibitors Pipeline: 185 Drugs - Majority Oncogene Inhibitors in Preclinical Phase: 105 Drugs - Proto Oncogene Protein c met Inhibitors Pipeline: 42 Drugs - Proto Oncogene Protein c-akt Inhibitors: 39 Drugs - Marketed Oncogene Inhibitors: 22 Drugs - Marketed Proto-Oncogene Protein c-bcl-2 Inhibitors: 8 Drugs Companies Mentioned - ArQule Inc - AstraZeneca - Biogen Idec - Boehringer Ingelheim - Celgene Corporation - Constellation Pharmaceutical - Epizyme Pharmaceutical - GalaxoSmithKline - Genentech - Incyte Corporation - Johnson & Johnson - Merck - Novartis - Onyx pharmaceuticals - Pfizer For more information visit http://www.researchandmarkets.com/research/v4ktq5/oncogene
JNJ: 100.43 (+0.13), BIIB: 423.57 (+1.46), MRK: 57.69 (+0.03), INCY: 107.98 (-1.20), ARQL: 2.11 (-0.03), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
Incyte (INCY) Is Strong On High Volume Today
at The Street - Mon Apr 13, 9:06AM CDT
Trade-Ideas LLC identified Incyte (INCY) as a strong on high relative volume candidate
INCY: 107.98 (-1.20)
10 Largest Companies by Market Cap in Biotech
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 11, 2:02PM CDT
Source: Celgene Big bucks are being made in biotech. That's clear from the sizzling performance of the industry. If five years ago you had invested $1,000 each in the current 10 biggest biotechs in terms of market cap, you would now have over...
BIIB: 423.57 (+1.46), VRTX: 132.85 (+0.65), PCYC: 256.98 (-0.77), BMRN: 121.08 (-0.16), GILD: 104.18 (-1.02), INCY: 107.98 (-1.20), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ABBV: 64.52 (+0.91), REGN: 472.63 (+9.41), CELG: 115.54 (+0.72)
The Reason Behind Geron Corporation's 25% Catapult Higher in March
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 09, 7:03AM CDT
What: Shares of Geron , a clinical-stage biopharmaceutical company currently developing an experimental drug known as imetelstat to fight hematologic myeloid malignancies, rocketed 25% higher in March, based on data from S&P Capital IQ ,...
JNJ: 100.43 (+0.13), GERN: 4.20 (-0.04), INCY: 107.98 (-1.20)
Incyte Rises 2.16% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 08, 4:45PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $89.34 to a high of $92.14. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $91.32 on volume of 730,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 107.98 (-1.20)
Incyte Set to Possibly Pullback After Yesterday's Rally of 2.16%
Comtex SmarTrend(R) - Wed Apr 08, 4:44PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $89.34 to a high of $92.14. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $91.32 on volume of 730,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 107.98 (-1.20)
Shares of INCY Up 15.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 08, 10:05AM CDT
SmarTrend identified an Uptrend for Incyte (NASDAQ:INCY) on January 23rd, 2015 at $78.42. In approximately 3 months, Incyte has returned 15.61% as of today's recent price of $90.66.
INCY: 107.98 (-1.20)
